Loading clinical trials...
Loading clinical trials...
A Phase II, Open-Label, Multicenter Study to Evaluate the Antitumor Efficacy of CO-1.01 for Infusion as Second-Line Therapy for Gemcitabine- Refractory Patients With Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression
Conditions
Interventions
CO-1.01
Locations
13
United States
Arizona Cancer Center at University of Arizona
Tucson, Arizona, United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
Palm Beach Institute / Collaborative Research Group
Boynton Beach, Florida, United States
University of Miami
Miami, Florida, United States
Piedmont Healthcare Research Institute (PHRI)
Atlanta, Georgia, United States
Norton Cancer Institute Research Program
Louisville, Kentucky, United States
Start Date
April 1, 2011
Primary Completion Date
March 1, 2013
Completion Date
March 1, 2013
Last Updated
March 11, 2019
NCT07409272
NCT06998940
NCT06381154
NCT07226856
NCT07344220
NCT01660971
Lead Sponsor
Clovis Oncology, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions